Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

2.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

3.

High-frequency measurements reveal spatial and temporal patterns of dissolved organic matter in an urban water conveyance.

Mihalevich BA, Horsburgh JS, Melcher AA.

Environ Monit Assess. 2017 Oct 30;189(11):593. doi: 10.1007/s10661-017-6310-y.

PMID:
29086038
4.

An urban observatory for quantifying phosphorus and suspended solid loads in combined natural and stormwater conveyances.

Melcher AA, Horsburgh JS.

Environ Monit Assess. 2017 Jun;189(6):285. doi: 10.1007/s10661-017-5974-7. Epub 2017 May 23.

PMID:
28536909
5.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

6.

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Parrish C, Scott GB, Migneco G, Scott KJ, Steele LP, Ilett E, West EJ, Hall K, Selby PJ, Buchanan D, Varghese A, Cragg MS, Coffey M, Hillmen P, Melcher AA, Errington-Mais F.

Leukemia. 2015 Sep;29(9):1799-810. doi: 10.1038/leu.2015.88. Epub 2015 Mar 27.

7.

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Jul;96(Pt 7):1533-50. doi: 10.1099/vir.0.000098. Epub 2015 Feb 23. Review.

8.

Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.

Clin Exp Immunol. 2015 Apr;180(1):98-107. doi: 10.1111/cei.12562.

9.

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12. doi: 10.1158/1078-0432.CCR-14-1770. Epub 2014 Nov 25.

10.

Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses.

Dave RV, Jebar AH, Jennings VA, Adair RA, West EJ, Errington-Mais F, Toogood GJ, Melcher AA.

Surgeon. 2014 Aug;12(4):210-20. doi: 10.1016/j.surge.2014.01.001. Epub 2014 Feb 4. Review.

PMID:
24502935
11.

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450. Epub 2013 Sep 18.

12.

Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells.

Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Sahi S, Adair RA, Mahmoud AB, Sad S, Bell JC, Makrigiannis AP, Melcher AA, Auer RC.

Clin Cancer Res. 2013 Sep 15;19(18):5104-15. doi: 10.1158/1078-0432.CCR-13-0246. Epub 2013 Jul 23.

13.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

14.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Review. Erratum in: Expert Opin Biol Ther. 2013 Jan;13(1):147.

PMID:
23140488
15.

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.

16.

What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?

Donnelly OG, Melcher AA, Vile RG, Pulido J.

Immunotherapy. 2012 Aug;4(8):749-51. doi: 10.2217/imt.12.65. No abstract available.

17.

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.

PMID:
22925693
18.

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

19.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

20.

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA.

Sci Transl Med. 2012 Jun 13;4(138):138ra77. doi: 10.1126/scitranslmed.3003578.

21.

A Herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures.

Turrell SJ, Macnab SA, Rose A, Melcher AA, Whitehouse A.

Int J Oncol. 2012 Jun;40(6):2081-9. doi: 10.3892/ijo.2012.1394. Epub 2012 Mar 1.

PMID:
22396105
22.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

23.

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS.

Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12.

24.

Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Hall K, Scott KJ, Rose A, Desborough M, Harrington K, Pandha H, Parrish C, Vile R, Coffey M, Bowen D, Errington-Mais F, Melcher AA.

Biores Open Access. 2012 Jan;1(1):3-15. doi: 10.1089/biores.2012.0205.

25.

Measles virus causes immunogenic cell death in human melanoma.

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA.

Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205. Epub 2011 Dec 15.

26.

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.

Win SJ, McMillan DG, Errington-Mais F, Ward VK, Young SL, Baird MA, Melcher AA.

Br J Cancer. 2012 Jan 3;106(1):92-8. doi: 10.1038/bjc.2011.538. Epub 2011 Dec 1.

27.

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP.

PLoS One. 2011;6(9):e22842. doi: 10.1371/journal.pone.0022842. Epub 2011 Sep 6.

28.

Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.

West EJ, Scott KJ, Jennings VA, Melcher AA.

Br J Cancer. 2011 Sep 6;105(6):787-95. doi: 10.1038/bjc.2011.290. Epub 2011 Aug 16.

29.

Recent clinical experience with oncolytic viruses.

Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA.

Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. Review.

PMID:
21740364
30.

Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA.

Clin Cancer Res. 2011 May 1;17(9):2767-76. doi: 10.1158/1078-0432.CCR-10-3266. Epub 2011 Mar 9.

31.

Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.

Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ.

Mol Ther. 2010 Sep;18(9):1599-605. doi: 10.1038/mt.2010.120. Epub 2010 Jun 29.

32.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

33.

The evolving role of dendritic cells in cancer therapy.

Ilett EJ, Prestwich RJ, Melcher AA.

Expert Opin Biol Ther. 2010 Mar;10(3):369-79. doi: 10.1517/14712590903559830. Review.

PMID:
20132058
34.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

Merrick AE, Ilett EJ, Melcher AA.

Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Review.

PMID:
19943208
35.

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

J Immunol. 2009 Oct 1;183(7):4312-21. doi: 10.4049/jimmunol.0901074. Epub 2009 Sep 4.

36.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

37.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

38.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA.

Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29. Epub 2009 Mar 12.

39.

Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors.

Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ.

Cancer Res. 2008 Dec 1;68(23):9771-8. doi: 10.1158/0008-5472.CAN-08-1911.

40.

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2008 Nov 15;14(22):7358-66. doi: 10.1158/1078-0432.CCR-08-0831.

41.

The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma.

Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, O'Donnell D, Pandha HS, Selby PJ, Banks RE, Merrick AE, Melcher AA.

BJU Int. 2009 Mar;103(6):740-6. doi: 10.1111/j.1464-410X.2008.08113.x. Epub 2008 Oct 24.

42.

Oncolytic viruses: a novel form of immunotherapy.

Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F.

Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581. Review.

43.

Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery.

Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, Hingorani M, Nutting CM, Kelly M, Harris P, Pandha H, Melcher AA, Vile RG, Porter C, Harrington KJ.

Gene Ther. 2009 Jan;16(1):78-92. doi: 10.1038/gt.2008.140. Epub 2008 Sep 11.

PMID:
18784747
44.

OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions.

Hill KS, Errington F, Steele LP, Merrick A, Morgan R, Selby PJ, Georgopoulos NT, O'Donnell DM, Melcher AA.

J Immunol. 2008 Sep 1;181(5):3108-15.

45.

Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.

Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ.

Clin Cancer Res. 2008 Aug 1;14(15):4915-24. doi: 10.1158/1078-0432.CCR-07-4049.

46.

Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, Melcher AA.

J Immunother. 2008 Sep;31(7):620-32. doi: 10.1097/CJI.0b013e31818213df.

47.

Immunotherapeutic potential of oncolytic virotherapy.

Prestwich RJ, Harrington KJ, Vile RG, Melcher AA.

Lancet Oncol. 2008 Jul;9(7):610-2. doi: 10.1016/S1470-2045(08)70163-3. No abstract available.

PMID:
18598928
48.

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA.

Gene Ther. 2008 Sep;15(18):1257-70. doi: 10.1038/gt.2008.58. Epub 2008 Apr 10.

49.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ.

Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6.

PMID:
18323793
50.

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ.

Clin Cancer Res. 2008 Feb 1;14(3):912-23. doi: 10.1158/1078-0432.CCR-07-1400.

Supplemental Content

Loading ...
Support Center